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Summary
Objective: To assess the immunogenicity of a fully liquid diphtheria—tetanus—five component
acellular pertussis—inactivated poliomyelitis—Haemophilus influenzae type b (DTaP—IPV—Hib)
conjugate vaccine compared to DTaP—IPV and lyophilized Hib conjugate vaccines given simulta-
neously at separate sites as a three-dose primary vaccination in Taiwanese infants.
Methods: Two hundred infants were randomized to receive either DTaP—IPV—Hib or DTaP—IPV
plus Hib vaccine at 2, 4, and 6 months of age. Both combined vaccines contained the same five
pertussis antigens: pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN),
fimbriae 2 and 3 (FIM 2&3). Antibody concentrations were measured before the first and after the
third dose. Reactogenicity was evaluated from parental reports. All subjects received hepatitis B
vaccine at 0, 1, and 6 months of age following the national vaccination schedule of Taiwan.
Results: The immunogenicity after the third dosewas high for each vaccine antigen in both groups,
and the vaccines had low reactogenicity. Statistical analysis showed no differences in the immune
responses to the fully liquid DTaP—IPV—Hib vaccine compared with those to the DTaP—IPV plus Hib
control vaccines, notably the anti-PRP (polyribose ribitol phosphate capsular polysaccharide) res-
ponse, with 97—99% of infants having concentrations1.0 mg/mL. Approximately 95% of all infants
developed seroprotective levels of anti-hepatitis B surfaceantigen (HBs) antibodies (10 mIU/mL).§ Presented at the 11th International Congress on Infectious Diseases, Cancun, Mexico, March 5—7, 2004 as ‘‘Immunogenicity and safety of a
fully liquid DTaP—IPV—Hib vaccine given as a three-dose primary vaccination in Taiwanese infants’’.
* Corresponding author. Tel.: +33 4 3737 7258; fax: +33 4 3737 7171.
E-mail address: Esteban.Ortiz@sanofipasteur.com (E. Ortiz).
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130 T.Y. Lin et al.Conclusions: Both combination vaccines had similar high immunogenicity for each antigen, and
both were well tolerated. Thus, inclusion of a Haemophilus influenzae type b conjugate vaccine in
the combination did not result in clinically significant decrease in the PRP response or increase
reactogenicity. The fully liquid pentavalent vaccine has the advantages of not requiring recon-
stitution and of administration as a single injection.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The increasing complexity and inconvenience of childhood
vaccination programs may reduce acceptance of, and com-
pliance with, recommended schedules. The completion of all
the vaccine doses in a routine childhood immunization sche-
dule requires a great deal of commitment from the child’s
parents and physicians. Development of highly immunogenic
and safe multivalent combinations based on acellular per-
tussis (DTaP (diphtheria—tetanus—acellular pertussis)) vac-
cines is a key step towards more realistic childhood
immunization schedules that are mutually acceptable to
the recipient, their parents, and healthcare professionals.
The use of combination vaccines decreases the number of
visits required, the number of injections required at each
visit, and may also reduce reactogenicity compared with
individually administered vaccines. The resulting simplifica-
tion of immunization schedules may enable caregivers to
improve vaccination coverage, dispense a less time-consum-
ing vaccination schedule, and may also decrease administra-
tion costs.
Combination vaccines containing acellular pertussis anti-
gens are safe, immunogenic, and effective in preventing
pertussis in infants.1 One such vaccine (TripacelTM, or Dap-
tacelTM, Sanofi Pasteur) containing five pertussis antigens —
pertussis toxoid (PT), filamentous hemagglutinin (FHA), per-
tactin (PRN), and fimbriae 2 and 3 (FIM2&3) — was found to
have better reactogenicity and similar immunogenicity when
compared to whole cell pertussis vaccines in controlled
clinical studies, and was 85% effective in preventing pertussis
in large field trials.2—5 The vaccines evaluated in this study
contain the same five acellular pertussis antigens.
The formulation of new vaccines in which several com-
ponents are combined in a single injection is complex,
because the combination of different antigens must not
adversely affect the immunogenicity of each component
or the safety profile. Consequently, it is important to deter-
mine that each component included in a combination vac-
cine is immunogenic and safe when administered according
to the recommended national schedule for routine infant
immunization. PediacelTM (Sanofi Pasteur), the pentavalent
vaccine evaluated in this study, is a fully liquid combination,
and unlike other similar products, does not require the
reconstitution of a lyophilized Hib conjugate vaccine
(PRP  T, polyribose ribitol phosphate conjugated to tetanus
protein) with liquid DTaP immediately before injection. It is
thus possible to protect infants against five diseases with a
single injection. Eliminating the need for Hib vaccine recon-
stitution decreases the overall time required for adminis-
tration, and avoids potential errors in preparation, mixing,
and injection of the vaccine. PediacelTM has been licensed in
the UK, Canada, and other countries, including the Philip-
pines and Malaysia.The present article reports on the safety and tolerability
of this fully liquid DTaP—IPV—PRP  Tcombination as well as
the immunogenicity of all the antigenic valences when given
to Taiwanese infants at 2, 4, and 6 months of age. The results
are compared with those obtained for DTaP—IPV vaccine
(QuadracelTM) and PRP  Tconjugate (ActHibTM) control vac-
cines given concomitantly at different injection sites, and
which have confirmed high immunogenicity and safety.6
Methods
This open, randomized, and controlled study recruited and
enrolled subjects who visited a healthy baby clinic at the
Chang-Gung Children’s Hospital, Taoyuan, Taiwan for routine
vaccinations. The study was conducted in accordance with
the Declaration of Helsinki Good Clinical Practice and applic-
able International Conference on Harmonization (ICH) guide-
lines. Witnessed, written informed consent was obtained
from the parents or guardians of all subjects before study
entry. The study protocol, amendments, and consent form
were approved by the study center Ethical Review Commit-
tee before initiation of the study. As the DTaP—IPV—PRP  T
and DTaP—IPV plus PRP  T vaccines were not marketed in
Taiwan, the study file was also submitted for approval by the
Taiwanese health authorities.
Subjects
Eligible subjects were healthy infants eight weeks of age or
older who had received hepatitis B vaccine at birth and also
at one month of age. Exclusion criteria included known or
suspected disease of the immune system, including human
immunodeficiency virus (HIV) infection; major congenital
malformation or condition; serious illness or malignancy;
history of neurological disorders or seizures; mother with
known or suspected liver disease; any known allergies or
reactions likely to be exacerbated by any component of the
study vaccines; treatment with immunosuppressive thera-
pies (excluding inhaled and topical steroids) for more than 14
days; current or planned receipt of immunoglobulins or any
blood-derived products; previous immunization against
diphtheria, tetanus, pertussis, Hib, or poliomyelitis; and
prior vaccination other than Bacillus Calmette—Guerin
(BCG) and hepatitis B.
Vaccines and vaccine schedule
Subjects were randomized equally to receive either a fully
liquid DTaP—IPV—PRP  Tconjugate vaccine (PediacelTM) or a
DTaP—IPV vaccine (QuadracelTM) plus PRP  T vaccine (Act-
HIBTM) given concomitantly at separate sites, at 2, 4, and 6
months of age. Subjects were allocated one of the two study
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list of random numbers.
The study vaccines were produced and supplied by Sanofi
Pasteur (formerly Aventis Pasteur), and were administered by
intramuscular injection into the left (DTaP—IPV—PRP  Tand
DTaP—IPV vaccines) or right (PRP  T vaccine) anterior
aspect of the thigh. Both acellular pertussis vaccines con-
tained 20 mg pertussis toxoid (PT), 20 mg filamentous hemag-
glutinin (FHA), 5 mg fimbrial antigens FIM2&3, and 3 mg
pertactin (PRN). The inactivated poliovirus (IPV) vaccine in
the fully liquid vaccine is produced in Vero cells, and the IPV
in the DTaP—IPV combination is produced in MRC5 human
diploid cell culture. All infants had received two doses of a
commercially available recombinant hepatitis B vaccine
(Engerix-B1, GlaxoSmithKline) separately from the study
vaccines, at birth and at one month of age before inclusion
in the study; all subjects received a third dose of hepatitis B
vaccine by intramuscular injection concomitantly with the
study vaccine, into the right thigh at six months of age. The
hepatitis vaccine used was not specified in the study proto-
col, and was chosen at the discretion of the investigator.
Immunology
Blood samples for antibody determination were collected
from each subject before immunization, and at one month
after the third vaccination at approximately seven months of
age. Frozen sera were transported to Sanofi Pasteur in Lyon,
France for serologic analysis. Antibodies to hepatitis B sur-
face antigen (HBs), anti-pertussis toxin (PT), anti-filamen-
tous hemagglutinin (FHA), anti-pertussis fimbrial
agglutinogens 2 and 3 (FIM2&3) and anti-pertactin (PRN),
were determined by enzyme-linked immunosorbent assay
(ELISA). Anti-polyribose ribitol phosphate capsular polysac-
charide (PRP) was measured by a Farr-type radioimmunoas-
say, as previously described.7 Anti-diphtheria antitoxin was
measured by seroneutralization; anti-tetanus antitoxin, by
ELISA; and antibodies to poliovirus types 1, 2, and 3, by
seroneutralization. Predefined seroprotection (SP) levels
were: anti-PRP 0.15 and 1.0 mg/mL; anti-polio 8 (1/
dil); anti-diphtheria and tetanus 0.01 IU/mL; and anti-
HBs 10 mIU/mL. Since there are no known correlates of
cut-off values for seroprotection for pertussis antibodies,
seroconversion/vaccine response rates were assessed as a
four-fold increase in antibody concentration from pre- to
post-primary vaccination.tpb -
Safety
All infants were monitored for 30 minutes after each injec-
tion for any immediate local or systemic reactions. Parents or
guardians recorded solicited local reactions (injection site
redness, swelling, and pain/tenderness) or solicited systemic
events (fever (rectal temperature 38 8C), drowsiness, unu-
sual fussiness, unusual crying, loss of appetite, vomiting, and
diarrhea) on diary cards daily for eight days after each
vaccination. Any unsolicited local or systemic reactions that
occurred during the 30 days after each vaccination were
recorded (including date of onset, date of resolution, and
intensity). Temperature was monitored daily following the
eight-day period after vaccination if the child remained
feverish.Solicited and unsolicited local and systemic reactions
were graded as mild, moderate, or severe. Crying when
the limb was moved indicated severe injection site tender-
ness. Rectal temperature >40 8C and continuous crying for
more than three hours were also criteria for severe reactions.
Statistical analysis
For each vaccine group the seroprotection/seroconversion/
vaccine response rates one month after the third dose of
vaccine and their 95% confidence intervals (CIs) were calcu-
lated. Antibody concentrations or titers were further
described by geometric mean concentrations (GMCs), or
geometric mean titers (GMTs) in the case of polio, with
respective 95% CIs and reverse cumulative distribution curves
(RCDC). The primary study outcome was the percentage of
subjects with seroprotective anti-PRP antibody concentra-
tions (15 mg/mL) one month after the third dose of study
vaccine. Based on previous experience with these DTaP—IPV
and PRP  T vaccines a rate of 98% was expected in the
present study.6 The clinically relevant difference in seropro-
tection rate was set at 10%, and the one-sided type one error,
a, was set at 2.5%. Based on the above defined seroprotection
rates, the clinical acceptable difference, the type I error, and
on a power of 90%, an optimal sample size of 80 subjects per
group was required for a one-sided equivalence test. Esti-
mating that up to 20% of subjects might be excluded from a
per protocol analysis, it was planned to enroll 200 subjects.
Statistical evaluation of seroprotection or seroconver-
sion/vaccine response rates for each antigen one month
following the primary series was descriptive, using the 95%
CI of the between-group differences. The primary objective
was reached if the lower limit of the 95% CIs of the difference
between subjects receiving DTaP—IPV—PRP  T minus those
receiving DTaP—IPV and PRP  T concomitantly at separate
sites was above the pre-specified clinical limit of 10% (one-
sided equivalence test, a = 2.5%).
Results
Study population
As planned, a total of 200 subjects were randomized equally
to the two study groups. All subjects completed the study. No
subject discontinued the trial. The study population included
93 males (46.5%) and 107 females (53.5%). There were
slightly more females (62%) in the group given DTaP—IPV—
PRP  Tand slightly more males (55%) among those receiving
DTaP—IPVand PRP  Tconcomitantly. The mean age at enrol-
ment was 10 weeks.
Immunogenicity
The study vaccines in both groups were highly immunogenic
with respect to all antigens, diphtheria, tetanus, pertussis
(PT, FHA, PRN, and FIM 2&3), the three polio antigens, and
PRP, with no significant differences in vaccine response or
seroprotection rate to any antigen observed between the
groups (Table 1). Seroprotection, seroconversion/vaccine
response rates (4-fold increase in antibody concentrations
from pre- to post-primary vaccination), were at least 93%. A
total of 97% of subjects in the DTaP—IPV— PRP  T group and
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Table 1 Seroprotection/vaccine response rates for all vaccine antigens, and differences between the groupsa
Antibody Seroprotection/vaccine response Difference
DTaP—IPV—PRP  T DTaP—IPV + PRP  T DTaP—IPV + PRP  T minus
DTaP—IPV—PRP  T
% (95% CI) % (95% CI) % (95% CI)
PRP  0.15 mg/mL 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
PRP  1.0 mg/mL 97.0 (91.5; 99.4) 99.0 (94.6; 100) 2 (2.9; 7.5)
D  0.01 IU/mL 100 (96.4; 100) 99.0 (94.6; 100) 0 (3.7; 3.7)
T  0.01 IU/mL 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
PT 4-fold increase 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
FHA 4-fold increase 94.0 (87.4; 97.8) 93.0 (86.1; 97.1) 1 (8.5; 6.4)
PRN 4-fold increase 98.0 (93.0; 99.8) 97.0 (91.5; 99.4) 1 (6.6; 4.4)
FIM 2&3 4-fold increase 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
Polio type 1  8/dil 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
Polio type 2  8/dil 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
Polio type 3  8/dil 100 (96.4; 100) 100 (96.4; 100) 0 (3.7; 3.7)
HBs  10 mIU/mL 95.7 (89.2; 98.8) 94.4 (87.5; 98.2) 1.3 (8.5; 5.8)
1/dil = reciprocal of the dilution at which the minimum level of activity needed to neutralize or precipitate poliovirus antigen was retained.
a Vaccine administered at 2, 4, and 6 months of age. All subjects received hepatitis B vaccination at 0, 1, and 6 months of age.99% in the DTaP—IPV plus PRP  T group had seroprotective
levels of anti-PRP 1.0 mg/mL one month after completing
the three-dose primary vaccination schedule. Seroprotection
rates for hepatitis B were between 94% and 96%.
The 95% CIs of the between-group differences demon-
strates the non-inferiority of group DTaP—IPV—PRP  T to
group DTaP—IPV plus PRP  T following primary vaccination
in terms of seroprotection, and seroconversion/vaccine
response to all antigens. Indeed, the observed differences
in immune response between the groups were all between 2%
(95% CI: 2.9;7.5) for anti-PRP1.0 mg/mL and1.3% (95%:
8.5; 5.8) for anti-HBs 10 mIU/mL.
Pre- and post-primary vaccination GMCs (GMTs for anti-
polio antibodies) are summarized in Table 2. Anti-PRP GMCs
were high in both groups (at least 11.4 mg/mL) following
vaccination. Anti-polio GMTs were at least 1082 1/dil for
type 1, 2504 1/dil for type 2, and 1607 1/dil for type 3. Anti-
HB antibody concentrations were over 600 IU/mL in both
study groups. The reverse cumulative distribution curvesTable 2 Geometric mean concentrations of antibodies to study
DTaP—IPV—PRP  T
Prevaccination Post-pri
GMC (95% CI) GMC (95
Anti-PRP (mg/mL) 0.065 (0.051; 0.083) 11.4 (9.
Anti-PT (EU/mL) 3.42 (3.04; 3.85) 221 (20
Anti- FHA (EU/mL) 3.96 (3.34; 4.69) 117 (10
Anti-PRN (EU/mL) 1.84 (1.66; 2.04) 82.3 (71
Anti FIM2&3 (EU/mL) 9.15 (8.54; 9.80) 823 (72
Anti-polio type 1 (1/dil) 6.07 (4.77; 7.71) 1082 (89
Anti-polio type 2 (1/dil) 12.6 (9.94; 15.9) 2504 (20
Anti-polio type 3 (1/dil) 7.60 (6.04; 9.56) 1607 (13
Anti-tetanus (IU/mL) 0.136 (0.096; 0.192) 5.66 (5.
Anti-diphtheria (IU/mL) 0.005 (0.004; 0.006) 2.37 (1.
Anti-HBs (IU/mL) 16.6 (10.5; 26.1) 633 (40
1/dil = reciprocal of the dilution at which the minimum level of activity(RCDCs) in Figures 1 and 2 show similar anti-pertussis and
anti-poliovirus antibody titers in both study groups after
primary immunization.
Safety and reactogenicity
All study vaccines were safe and well tolerated. Both acel-
lular pertussis-based combined vaccines elicited similar low
rates of solicited local and systemic reactions, the large
majority of which were transient and mild to moderate.
The inclusion of PRP  T in the combination vaccine did
not increase reactogenicity compared with the PRP  T vac-
cine given concomitantly (Table 3).
Serious adverse events
A total of 27 serious adverse events (SAEs) were reported in
21 subjects (13 from the combined vaccine group and eight
from the group given concomitant vaccinations). They werevaccine antigens
DTaP—IPV + PRP  T
mary Prevaccination Post-primary
% CI) GMC (95% CI) GMC (95% CI)
35; 14.0) 0.056 (0.046; 0.069) 21.7 (17.3; 27.2)
0; 245) 3.62 (3.16; 4.16) 216 (193; 243)
4; 132) 4.33 (3.57; 5.26) 104 (93.4; 116)
.8; 94.2) 1.98 (1.76; 2.24) 98.8 (86.3; 113)
6; 934) 9.14 (8.59; 9.73) 799 (684; 933)
2; 1314) 6.66 (5.20; 8.54) 1218 (957; 1550)
91; 2999) 9.72 (7.76; 12.2) 3180 (2686; 3766)
57; 1903) 6.42 (5.20; 7.92) 1920 (1578; 2335)
13; 6.23) 0.101 (0.071; 0.146) 6.41 (5.63; 7.29)
97; 2.85) 0.005 (0.004; 0.006) 1.59 (1.32; 1.90)
5; 989) 17.3 (11.0; 27.2) 611 (373; 1002)
needed to neutralize or precipitate poliovirus antigen was retained.
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Figure 1 Reverse Cumulative Distribution Curves (RCDC) of anti-pertussis antibody GMCs (EU/mL) following three doses of DTaP—
IPV—PRP—T or DTaP—IPV+PRP—T at 2, 4, and 6 months of age.all considered by the investigator to be unrelated to vaccina-
tion and they all resolved. Most of the SAEs were common
events or diagnoses observed in infancy, for example, viral
infection, urinary tract infection, bronchiolitis, or gastro-
enteritis. No cases of hypotonic hyporesponsive episodes or
seizures were reported within one month after vaccination.
No withdrawals occurred because of SAEs.
Solicited local and systemic reactions
No immediate local or systemic adverse events occurred
within 30 minutes after vaccination. All study vaccines were
associated with a low incidence of solicited local and sys-
temic adverse reactions (Table 3). Most of the symptoms
occurred within the 72 hours after vaccination and were mild
or moderate, and transient in nature. Redness was the mostfrequent local reaction, observed after 14.7% of doses given
in the DTaP—IPV—PRP  T group, and 15% and 9% of injections
in the group given DTaP—IPV plus PRP  T. Loss of appetite
was the most frequent systemic reaction, observed following
23.3% and 22% of DTaP—IPV—PRP  T and DTaP—IPV plus
lyophilized PRP  T doses, respectively. In only one case
was loss of appetite reported as severe. The incidence of
fever was low, between 7% and 10.3% with no occurrences of
severe fever. The rates of severe solicited local and systemic
reactions were very low in both study groups.
Unsolicited reactions
Of all doses administered to the 200 study subjects, three
were considered by the investigator to be associated with an
unsolicited systemic reaction occurring within 30 days of
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Figure 2 Reverse Cumulative Distribution Curves (RCDC) of anti-poliovirus types 1, 2, and 3, antibody GMTs (dil:U) after three doses
of DTaP—IPV—PRP—T or DTaP—IPV+PRP—T at 2, 4, and 6 months of age.vaccination. In the DTaP—IPV plus PRP  T group, one subject
had transient gastroenteritis four days after dose three. The
gastroenteritis was preceded by one episode of diarrhea that
occurred the day after the same dose (recorded as a solicited
symptom related to vaccination). One subject given DTaP—
IPV—PRP  T had decreased activity of the left leg, which had
received the injection, that resolved within two days. A
second infant in the same group had fussiness and irritability
beginning four days after the second dose and lasting one day.
This was preceded by another episode of fussiness and irrit-
ability occurring a day after the same dose, which was
recorded as a solicited reaction.
Discussion
The current study was conducted to compare the immuno-
genicity and safety of the fully liquid DTaP—IPV—PRP  Tvaccine with that of DTaP—IPV plus PRP  T vaccine given
concomitantly at separate sites as a three-dose primary
vaccination in healthy Taiwanese infants. A previous inves-
tigation in Canadian children confirmed the high immuno-
genicity of the DTaP—IPV plus PRP  T vaccines given
concomitantly and which were the control vaccines used in
this study.6 All infants enrolled in this study also received
hepatitis B vaccination at 0, 1, and 6 months of age according
to the national vaccination schedule of Taiwan.
Recent studies with other acellular pertussis combination
vaccines containing a conjugated Hib antigen have shown
significant reductions in the anti-PRP GMCs when the Hib
vaccine is combined with the other valences in a single
injection.8—10 In this study, all infants showed high immune
responses to all vaccine antigens, with no clinically signifi-
cant differences in immune response between the DTaP—
IPV—PRP  T study and control vaccines for any of the anti-
gens evaluated. All subjects developed an anti-PRP antibody
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Table 3 Incidence of solicited local or vaccine-related local and systemic adverse reactions within the eight days following
injection (regardless of dose)a
Type of reactionb DTaP—IPV—PRP  T DTaP—IPV + PRP  T
n = 300 n = 300
% % %
Any local Any 18.7 20.3 12
Severe 0.7 1 0.3
Redness Any 14.7 15 9
Severe 0.3 0.3 0
Swelling Any 10.7 11.7 5.3
Severe 0 0.3 0
Pain Any 6.7 8.3 5
Severe 0.3 0.3 0.3
Any systemic Any 39.0 44.0
Severe 6 8.3
Feverc Any 7.0 10.3
Severe 0 0
Drowsiness Any 12.3 17.0
Severe 4 5.0
Fussiness Any 14.3 16.3
Severe 0.3 2.7
Unusual crying Any 18.7 15.0
Severe 0.3 3.0
Loss of appetite Any 23.3 22.0
Severe 0.3 0
Vomiting Any 6.3 7.7
Severe 0.3 0
Diarrhea Any 6.7 8.7
Severe 1.0 0.7
a Vaccine administered at 2, 4, and 6 months of age. All subjects received hepatitis B vaccination at 0, 1, and 6 months of age.
b Having a possible, probable, or definite relationship to the vaccination (regardless of intensity).
c Fever = rectal temperature 38.0 8C. n = number of injections administered.concentration of at least 0.15 mg/mL, which has been estab-
lished to provide immediate protection against Hib infection,
and 97—99% of subjects developed a level of at least 1.0 mg/
mL, which is considered to indicate long-term protection
based on the rate of decline of antibody titers.11,12 The
antibody responses to the other vaccine antigens in both
study groups, based on the antibody GMTs and 95% CIs, also
show no evidence of interference when the PRP  T vaccine
was included in the fully liquid combination compared with
concomitant administration. The convenience of the single
injection with DTaP—IPV—PRP  T is therefore not associated
with a lower PRP  T seroprotective response.
Both the fully liquid vaccine and concomitant vaccination
elicited high immunogenicity for each antigenic component.
All subjects had antibody concentrations that were above
levels considered to be protective against diphtheria and
tetanus. All subjects also achieved seroprotective titers for
neutralizing antibody to all three poliovirus types with DTaP—
IPV—PRP  T (IPV produced on Vero cell cultures) and with
DTaP—IPV (IPV produced on MRC5 cell cultures). Thus,
although the IPVs were produced on different cell lines,
there were no differences between the two vaccines in
the immune responses evaluated.
Although there are no established serological markers of
protection against pertussis, the high antibody responses
against the five acellular pertussis components, PT, FHA,PRN, and FIM2&3, were comparable with those observed
to elicit a protective efficacy of 85% in a Swedish field trial
in which the same acellular pertussis components were used,
and similar to those observed in a previous study of the DTaP—
IPV control vaccine.4,5 The seroprotection rates against
hepatitis B were also high in both groups. Thus, the con-
comitant administration of these acellular pertussis-based
combinations plus PRP  T vaccine did not affect the immu-
nogenicity of hepatitis B vaccine given according to the
Taiwan national schedule at 0, 1, and 6 months of age.
Both acellular pertussis-based combined vaccines elicited
similar low rates of solicited local and systemic reactions, the
large majority of which were transient andmild to moderate.
There were no study withdrawals because of adverse events
and no hypotonic hyporesponsive episodes or seizures
associated with the vaccinations. The low reactogenicity
observed in both study groups shows that inclusion of
PRP  T in the combination vaccine does not increase
reactogenicity compared with the PRP  T vaccine given
concomitantly, and reinforces the excellent safety profiles
expected of acellular pertussis vaccines.3
The immunogenicity and safety results observed in this
clinical study are similar to previous data generated in
Taiwan using the same five-component acellular pertussis,
diphtheria, and tetanus toxoid vaccine (DTaP) combined, or
given concomitantly with PRP  T vaccine.13 In that study,
136 T.Y. Lin et al.anti-PRP GMC values were 11.8 mg/mL in the combined
group compared with 13.0 mg/mL in the concomitant group.
The data from that study also clearly show that these DTaP
and PRP  T vaccines can be combined without clinically
significant interaction. A similar vaccine containing the same
five acellular pertussis antigens and PRP  T, plus IPV pro-
duced on MRC5 cell culture, given as a single injection
(PentacelTM) has been in routine use in Canada since 1997.
National surveillance in Canada between 2001 and 2003 has
confirmed the effectiveness of that vaccine against pertussis
and invasive Hib disease as well as improved safety compared
to the whole cell pertussis combination vaccine that it
replaced.14,15 Concomitant administration of hepatitis B
vaccine with the two acellular pertussis-based vaccines in
this study was carried out with satisfactory safety and immu-
nogenicity, demonstrating the compatibility of these two
vaccines.
Conclusion
This study shows that DTaP—IPV—Hib provides protection
against five diseases in a single, convenient, premixed for-
mulation without compromising safety or tolerability, or the
immunogenicity of the individual component antigens. The
fully liquid pentavalent vaccine has been shown to be simi-
larly highly immunogenic and as well tolerated as DTaP—IPV
plus Hib vaccine; however, in contrast with the latter regi-
men, no reconstitution is required, and it can be adminis-
tered as a single injection. The response to Hib PRP antigen
as measured by the proportion of subjects with anti-PRP
levels 1.0 mg/mL was not reduced in DTaP—IPV—Hib com-
pared with the DTaP—IPV plus Hib vaccine combination, so
the convenience of the single injection with DTaP—IPV—Hib
is not at the expense of lessened protection against Hib
disease.
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